Literature DB >> 25527136

In vitro screening for drug repositioning.

Graeme F Wilkinson1, Kevin Pritchard2.   

Abstract

Drug repositioning or repurposing has received much coverage in the scientific literature in recent years and has been responsible for the generation of both new intellectual property and investigational new drug submissions. The literature indicates a significant trend toward the use of computational- or informatics-based methods for generating initial repositioning hypotheses, followed by focused assessment of biological activity in phenotypic assays. Another viable method for drug repositioning is in vitro screening of known drugs or drug-like molecules, initially in disease-relevant phenotypic assays, to identify and validate candidates for repositioning. This approach can use large compound libraries or can focus on subsets of known drugs or drug-like molecules. In this short review, we focus on ways to generate and validate repositioning candidates in disease-related in vitro and phenotypic assays, and we discuss specific examples of this approach as applied to a variety of disease areas. We propose that in vitro screens offer several advantages over biochemical or in vivo methods as a starting point for drug repositioning.
© 2014 Society for Laboratory Automation and Screening.

Keywords:  in vitro; repositioning; review; screening

Mesh:

Year:  2014        PMID: 25527136     DOI: 10.1177/1087057114563024

Source DB:  PubMed          Journal:  J Biomol Screen        ISSN: 1087-0571


  16 in total

1.  CDK4/6 inhibitor palbociclib suppresses IgE-mediated mast cell activation.

Authors:  Yi-Bo Hou; Kunmei Ji; Yue-Tong Sun; Li-Na Zhang; Jia-Jie Chen
Journal:  J Transl Med       Date:  2019-08-20       Impact factor: 5.531

2.  Screening a Commercial Library of Pharmacologically Active Small Molecules against Staphylococcus aureus Biofilms.

Authors:  Nelson S Torres; Johnathan J Abercrombie; Anand Srinivasan; Jose L Lopez-Ribot; Anand K Ramasubramanian; Kai P Leung
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

Review 3.  Small-Molecule Screens: A Gateway to Cancer Therapeutic Agents with Case Studies of Food and Drug Administration-Approved Drugs.

Authors:  Nathan P Coussens; John C Braisted; Tyler Peryea; G Sitta Sittampalam; Anton Simeonov; Matthew D Hall
Journal:  Pharmacol Rev       Date:  2017-10       Impact factor: 25.468

4.  Aurora kinase inhibitor tozasertib suppresses mast cell activation in vitro and in vivo.

Authors:  Li-Na Zhang; Kunmei Ji; Yue-Tong Sun; Yi-Bo Hou; Jia-Jie Chen
Journal:  Br J Pharmacol       Date:  2020-04-06       Impact factor: 8.739

Review 5.  Compounds with anti-influenza activity: present and future of strategies for the optimal treatment and management of influenza. Part II: Future compounds against influenza virus.

Authors:  R Gasparini; D Amicizia; P L Lai; N L Bragazzi; D Panatto
Journal:  J Prev Med Hyg       Date:  2014-12

6.  Antimicrobial and Antibiofilm Activity of Synergistic Combinations of a Commercially Available Small Compound Library With Colistin Against Pseudomonas aeruginosa.

Authors:  Nelson S Torres; Daniel Montelongo-Jauregui; Johnathan J Abercrombie; Anand Srinivasan; Jose L Lopez-Ribot; Anand K Ramasubramanian; Kai P Leung
Journal:  Front Microbiol       Date:  2018-10-25       Impact factor: 5.640

7.  Repositioning organohalogen drugs: a case study for identification of potent B-Raf V600E inhibitors via docking and bioassay.

Authors:  Yisu Li; Binbin Guo; Zhijian Xu; Bo Li; Tingting Cai; Xinben Zhang; Yuqi Yu; Heyao Wang; Jiye Shi; Weiliang Zhu
Journal:  Sci Rep       Date:  2016-08-09       Impact factor: 4.379

8.  Repositioning of Omarigliptin as a once-weekly intranasal Anti-parkinsonian Agent.

Authors:  Bassam M Ayoub; Shereen Mowaka; Marwa M Safar; Nermeen Ashoush; Mona G Arafa; Haidy E Michel; Mariam M Tadros; Mohamed M Elmazar; Shaker A Mousa
Journal:  Sci Rep       Date:  2018-06-12       Impact factor: 4.379

9.  In Planta Preliminary Screening of ER Glycoprotein Folding Quality Control (ERQC) Modulators.

Authors:  Lucia Marti; Andrea Lia; Ida-Barbara Reca; Pietro Roversi; Angelo Santino; Nicole Zitzmann
Journal:  Int J Mol Sci       Date:  2018-07-23       Impact factor: 5.923

10.  Repurposing FDA-approved drugs against multiple proteins of SARS-CoV-2: An in silico study.

Authors:  Alfred Olaoluwa Akinlalu; Annapoorna Chamundi; Donald Terseer Yakumbur; Funmilayo I Deborah Afolayan; Ijeoma Akunna Duru; Michael Aderibigbe Arowosegbe; Ojochenemi Aladi Enejoh
Journal:  Sci Afr       Date:  2021-07-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.